Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 28.70 is 27% below its 5-year average of 39.11, near the low end of its 5-year range (15.83–140.46).
As of the fiscal period ended Tuesday, June 30, 2026. 0.14% below its 12-month average of 28.73.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 28.70.
CURRENT RATIO
28.70
CURRENT RATIO AVG TTM
28.73
CURRENT RATIO AVG 3Y
24.98
CURRENT RATIO AVG 5Y
39.11
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-0.14%
CURRENT VS 3Y AVG
+14.89%
CURRENT VS 5Y AVG
-26.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.76
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+663.18%
vs the sector median at left
Market Cap
$1.48B
Current Ratio
2.96
TTM Avg
2.86
3Y Avg
3.00
5Y Avg
3.00
Market Cap
$1.46B
Current Ratio
18.31
TTM Avg
12.63
3Y Avg
8.12
5Y Avg
8.12
Market Cap
$1.49B
Current Ratio
15.72
TTM Avg
30.76
3Y Avg
24.36
5Y Avg
24.36
Market Cap
$1.50B
Current Ratio
1.52
TTM Avg
1.81
3Y Avg
2.10
5Y Avg
3.34
Market Cap
$1.45B
Current Ratio
3.02
TTM Avg
3.13
3Y Avg
2.94
5Y Avg
3.03
Market Cap
$1.42B
Current Ratio
1.73
TTM Avg
2.42
3Y Avg
2.71
5Y Avg
3.73
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GH Research PLC (GHRS) | $1.48B | 28.70 | 28.73 | 24.98 | 39.11 |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 2.96 | 2.86 | 3.00 | 3.00 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 18.31 | 12.63 | 8.12 | 8.12 |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | 15.72 | 30.76 | 24.36 | 24.36 |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 1.52 | 1.81 | 2.10 | 3.34 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 3.02 | 3.13 | 2.94 | 3.03 |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 5.00 | 2.75 | 2.21 | 2.87 |
| Certara, Inc. (CERT)vs › | $1.44B | 2.55 | 2.09 | 2.53 | 2.95 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | 1.73 | 2.42 | 2.71 | 3.73 |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 5.61 | 9.29 | 11.65 | 16.84 |
Current Ratio
28.70
Quick Ratio
28.70
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 28.70 |
| 2026-03-31 | 23.04 |
| 2025-12-31 | 34.13 |
| 2025-09-30 | 28.32 |
| 2025-06-30 | 29.49 |
| 2025-03-31 | 29.71 |
| 2024-12-31 | 17.23 |
| 2024-09-30 | 15.83 |
| 2024-06-30 | 19.60 |
| 2024-03-31 | 22.06 |
| 2023-12-31 | 24.49 |
| 2023-09-30 | 26.74 |
| 2023-06-30 | 25.38 |
| 2023-03-31 | 24.81 |
| 2022-12-31 | 37.07 |
| 2022-09-30 | 76.82 |
| 2022-06-30 | 86.02 |
| 2022-03-31 | 67.26 |
| 2021-12-31 | 101.80 |
| 2021-09-30 | 140.46 |
| 2021-06-30 | 63.76 |
| 2021-03-31 | 4.46 |
| 2020-12-31 | 24.03 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
